← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants
brexanolone
N06AX29
Forms & Strengths
- Intravenous solution: 5 mg/mL in 20 mL vials
Adult Dosing
- Postpartum depression: 90 mcg/kg/hour continuous IV infusion over 60 hours
- Titration: Hour 0 to 4: 30 mcg/kg/hour
- Hour 4 to 24: 60 mcg/kg/hour
- Hour 24 to 52: 90 mcg/kg/hour
- Hour 52 to 56: 60 mcg/kg/hour
- Hour 56 to 60: 30 mcg/kg/hour
Pediatric Dosing
- Safety and efficacy in pediatric patients not established
Indications
- Treatment of postpartum depression (PPD) in adults
Mechanism of Action
- Positive allosteric modulator of GABAA receptors
- Acts as an endogenous and synthetic neuroactive steroid
- Enhances GABA-mediated neuronal inhibition
Contraindications
- History of hypersensitivity to brexanolone
- End-stage renal disease (eGFR < 15 mL/min/1.73m2)
Adverse Reactions
- Excessive sedation and sudden loss of consciousness
- Somnolence
- Dry mouth
- Flushing or hot flush
- Upper respiratory tract infection
Drug Interactions
- CNS depressants (opioids, benzodiazepines): increased risk of severe sedation and respiratory depression
- Antidepressants: may enhance sedative effects
Curated Content: Needs Vetting Before Put to Clinical Use